Melatonin for Health & Longevity - Quick Reference Sheet

Melatonin for Health & Longevity

Created on 10/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Melatonin, the body's darkness hormone, is sold as an inexpensive supplement, or by prescription in some countries, for sleep and body-clock timing. It reliably helps reset the body clock after long flights and late-running sleep schedules, and helps people fall asleep slightly faster. Claims that it slows aging rest only on animal and laboratory work. Main risks are next-morning drowsiness and worse blood sugar handling when it overlaps meals. (Full Review)

Protocol

Physiological low dose
0.3 mg nightly
About 30 minutes before bedtime
Jet lag
0.5–5 mg
Near target bedtime at the destination; no gain above 5 mg
Best time of day
Evening only
For sleep, 30 minutes to three hours before bedtime; morning doses delay the clock
Time to effect
Jet lag relief
Within the trip
With doses at destination bedtime
Sleep onset
From the first nights
Prolonged-release benefits by three weeks
Bone density
Only after a year
Femoral neck gains in postmenopausal osteopenia

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • Children, except under medical supervision
  • People with epilepsy or taking anticoagulants, unless medically supervised
  • People with dementia using it for sleep
  • People hypersensitive to melatonin or product ingredients
  • People with autoimmune disease
  • People with liver impairment
Key Interactions
  • Fluvoxamine and quinolone antibiotics (ciprofloxacin), CYP1A2 inhibitors: Avoid fluvoxamine; caution with quinolones
  • Alcohol: Avoid
  • Sedative-hypnotics (sleep-inducing drugs: zolpidem, benzodiazepines): Caution; worsened impairment of coordination and driving
  • Calcium channel blockers (blood pressure drugs such as nifedipine): Caution; raised blood pressure
  • Cimetidine (an acid-reducing drug): Caution; raises melatonin levels
  • Immunosuppressants (anti-rejection and immune-dampening drugs such as tacrolimus): Caution (theoretical); risk of reduced immunosuppression
  • Sedating antihistamines (diphenhydramine, doxylamine): Caution (theoretical); additive sedation
  • Sedating supplements (valerian, kava, magnesium): Caution (theoretical); additive sedation
  • Glucose-lowering drugs (metformin, sulfonylureas, insulin): Monitor (theoretical); could blunt glucose control
  • Hormonal contraceptives and estrogens (ethinylestradiol): Monitor; raised melatonin exposure
  • CYP1A2 inducers (drugs that speed up this enzyme, such as carbamazepine): Monitor; may lower melatonin levels
  • Caffeine: Monitor; raises melatonin exposure (600 mg)
  • Tobacco smoking: Monitor; lowers melatonin exposure
  • Blood pressure-lowering supplements (garlic extract, beetroot nitrate): Monitor (theoretical); additive lowering of blood pressure
  • Glucose-lowering supplements (berberine, chromium): Monitor (theoretical); unpredictable effects on glucose control
  • Bright-light therapy and evening screens: Monitor (theoretical); evening bright light reduces its effect

Risk & Side Effects

  • High: Next-day drowsiness, headache, dizziness and nausea
  • Medium: Impaired glucose tolerance when doses overlap meals; menstrual cycle changes
  • Low: Heart failure signal with long-term use; worsening of seizures; fracture signal in middle-aged and older adults; nightmares, agitation and mood changes; heart rhythm disturbances
  • Speculative: Tumor promotion; immune activation in autoimmune disease

Monitoring

Marker Target Why
Fasting glucose 70–99 mg/dL Safety check: melatonin can impair glucose handling
HbA1c 4.0–5.6% Safety check for longer-term glucose effects
Blood pressure Below 120/80 mmHg Expected small decrease; safety check with nifedipine
LDL cholesterol Below 100 mg/dL Expected small decrease
INR (warfarin users only) No established target; change from own stable INR Safety check: case reports of altered clotting control
Femoral neck bone mineral density No established target; change from own baseline Expected increase

Cadence: Baseline before starting; 2 weeks (INR and blood pressure where relevant); 3 months (fasting glucose, HbA1c, blood pressure and lipids); then every 6–12 months; bone density scan repeated after one year

Qualitative Assessment

  • Time to fall asleep and night waking, from a sleep diary or wearable tracker
  • Morning grogginess, alertness and mood
  • Days needed to adjust after long-haul travel
  • Dream intensity and nightmares
  • Headache or migraine frequency